As shown in Fig. 2c, GBM (n = 30) with higher ETV2 expression had a median survival of 67.5 weeks, whereas the group with relatively lower ETV2 expression (n = 45) had a median survival of 123 weeks (P < 0.02). Here, ETV2 is linked to glioblastoma.